ReviewRSC advances2026
Hydrogel-based drug delivery systems for enhanced tumor therapy.
Review in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Development of Carboxymethyl Cellulose-Gelatin Aerogels for Urea Delivery.AAPS PharmSciTech · 2026Article
- Hydrogel co-delivery of 5-fluorouracil and siRNA attenuates TGF-β1-mediated MMT to prevent postoperative peritoneal metastasis and adhesion in colorectal cancer.Asian journal of pharmaceutical sciences · 2026Article
- Cell-Type-Tailored Hydrogels for Adoptive Cell Therapy in Cancer.Gels (Basel, Switzerland) · 2026Review
- Review
- The Trade-Off Between Sterility and Structural Integrity in Sterilized Alginate Hydrogels.Gels (Basel, Switzerland) · 2026Article
- From Smart Hydrogel Design to 4D-Printed Scaffolds: Emerging Paradigms in Precision Drug Delivery and Regenerative Wound Therapy.Gels (Basel, Switzerland) · 2026Review
- Bio-Polymers Based Functionalized Hydrogel Carriers for Targeted Oncology Therapies: Current Progress and Future Perspectives.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a major global health challenge, with current treatment modalities like surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy often hampered by limitations such as systemic toxicity, drug resistance, and an immuno-suppressive tumor microenvironment (TME). Hydrogel technology emerges as a transformative platform to overcome these hurdles. The unique three-dimensional network structure of hydrogels allows for high drug loading, localized sustained release, and exceptional tunability. This review highlights the innovative applications of hydrogel systems in enhancing various antitumor modalities, including chemotherapy, immunotherapy, radiotherapy, phototherapy, gene therapy, and their combinations. By enabling spatiotemporally controlled delivery and modulating the TME, hydrogels significantly improve therapeutic efficacy while minimizing off-target effects. The purpose of this study is to describe some of the latest developments in the use of hydrogels for the treatment of cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.